Passive immunotherapy for Alzheimer’s disease: challenges & future directions

• Published in: Journal of translational medicine Vol. 22; no. 1; pp. 430 - 10
• Main Authors: Yi, Ling Xiao, Tan, Eng King, Zhou, Zhi Dong
• Format: Journal Article
• Language: English
• Published: London BioMed Central 07.05.2024; BioMed Central Ltd; BMC
• Subjects: Alzheimer Disease - immunology; Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - immunology; Amyloid beta-Peptides - metabolism; Amyloid beta-protein; Analysis; Antibodies, Monoclonal - therapeutic use; Biomedical and Life Sciences; Biomedicine; Care and treatment; Commentary; Diagnosis; Dosage and administration; Humans; Immunization, Passive; Immunotherapy; Medicine/Public Health; Monoclonal antibodies; Neuroscience; Patient outcomes; Singapore
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-05248-x

Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising therapeutic approach in Alzheimer’s disease (AD). However, in a recent phase III clinical study, Sperling et al. (N Engl J Med 10.1056/NEJMoa2305032, 2023) reported that solanezumab, a monoclonal antibody targeting Aβ peptide, failed to slow cognitive decline in AD patients. Previously, three other anti-Aβ antibodies, bapineuzumab, crenezumab, and gantenerumab, have also failed to show similar beneficial effects. In addition, three humanized antibodies targeting tau protein failed in their phase II trials. However, other anti-Aβ antibodies, such as lecanemab (a humanized mAb binds to soluble Aβ protofibrils), donanemab (a humanized mAb binds to insoluble, N-terminal truncated form of Aβ peptides) and aducanumab (a human mAb binds to the aggregated form of Aβ), have been shown to slow the decline of cognitive functions in early stage AD patients. The specific targets used in passive immunotherapy in these clinical trials may explain the divergent clinical outcomes. There are several challenges and limitations of passive immunotherapy using anti-Aβ antibodies and long term longitudinal studies are needed to assess their efficacy, side effects and cost effectiveness in a wider spectrum of subjects, from pre-dementia to more advanced dementia. A combination therapeutic approach using both anti-Aβ antibodies and other pharmaceutical agents should also be explored.